Large Cell Neuroendocrine Carcinoma of the Lung (LCNEC) — a rare, high-grade pulmonary neuroendocrine tumor accounting for approximately 3% of all lung cancers (roughly 5,000–6,000 new cases annually in the United States), first codified in the 1999 WHO classification and now recognized as a distinct entity within the spectrum of pulmonary neuroendocrine tumors alongside typical carcinoid, atypical carcinoid, and small cell lung cancer (SCLC), defined by its unique combination of large cell morphology (large cells with abundant cytoplasm, prominent nucleoli, and vesicular nuclei — the morphologic features of non-small cell lung cancer) with histologic and immunohistochemical evidence of neuroendocrine differentiation (organoid, nested, trabecular, palisading, or rosette-forming growth patterns; expression of at least one neuroendocrine marker: synaptophysin, chromogranin A, CD56/NCAM, or neuron-specific enolase), high mitotic rate (≥11 mitoses per 2 mm²; median mitotic count 60–80 per 2 mm²), and large areas of necrosis, occupying an orphan clinical position where its morphologic NSCLC features, SCLC-like biological behavior, and distinct molecular landscape create diagnostic and therapeutic uncertainty that has defined management challenges for two decades — presents as a large, often centrally located pulmonary mass with frequent mediastinal lymph node involvement and early hematogenous metastases to brain, liver, bone, and adrenal glands, with an aggressive natural history featuring 5-year overall survival of 15–35% for resected disease and median survival of 8–12 months for advanced stage, and frequent de novo presentation at stage III–IV. Molecularly, LCNEC divides into two principal subtypes with distinct therapeutic implications: an SCLC-like subset characterized by RB1 inactivation and TP53 mutation (co-occurring in ~40% of LCNEC, analogous to the universal RB1/TP53 co-mutation in SCLC) that demonstrates sensitivity to platinum-etoposide chemotherapy; and an NSCLC-like subset characterized by STK11 mutations, KEAP1 mutations, and/or KRAS mutations (in ~40% of LCNEC, resembling the molecular landscape of lung adenocarcinoma) that may respond better to platinum-pemetrexed or NSCLC-type regimens. Actionable alterations including EGFR mutations, ALK fusions, ROS1 fusions, MET exon 14 skipping, BRAF V600E mutations, RET fusions, and NTRK fusions occur at low frequency (~5–10%) but determine targeted therapy eligibility in the rare patient harboring them; PD-L1 expression and tumor mutation burden inform immunotherapy eligibility. Standard resectable disease management integrates anatomic resection (lobectomy or pneumonectomy) with mediastinal lymph node dissection followed by adjuvant platinum-based chemotherapy, while advanced disease treatment follows platinum-etoposide (for SCLC-like LCNEC or combined SCLC-LCNEC) or platinum-pemetrexed (for NSCLC-like LCNEC without RB1 loss) regimens — histologic and molecular subtype routing that requires platforms managing synaptophysin/chromogranin biomarker results, RB1 status, and molecular profiling to deliver the right chemotherapy backbone.
LCNEC technology platforms — whether supporting thoracic surgery programs coordinating pulmonary resection (managing preoperative CT chest with PE protocol for tumor characterization, FDG-PET/CT for mediastinal and distant staging, EBUS-TBNA or mediastinoscopy for mediastinal lymph node sampling, endobronchial ultrasound results for central tumor assessment, preoperative pulmonary function testing for resectability assessment, intraoperative frozen section for margin status and lymph node involvement, VATS versus open lobectomy operative documentation), molecular pathology platforms performing LCNEC subtype routing (synaptophysin, chromogranin A, CD56, NCAM immunohistochemistry for neuroendocrine differentiation confirmation; RB1 IHC as surrogate for RB1 mutation; comprehensive NGS panel for STK11, KEAP1, KRAS, TP53, RB1, EGFR, ALK, ROS1, MET, BRAF, RET, NTRK mutations and fusions; PD-L1 expression by IHC; TMB determination), medical oncology platforms managing platinum-based chemotherapy and immunotherapy (platinum-etoposide or platinum-pemetrexed administration records, dose modification for hematologic and renal toxicity, granulocyte-colony stimulating factor administration records, immunotherapy toxicity monitoring), radiation oncology platforms managing thoracic irradiation and prophylactic cranial irradiation (PCI in SCLC-like LCNEC achieving complete response), and clinical trial enrollment platforms for a tumor where rarity makes trial enrollment critical to improving outcomes — must maintain the availability and performance standards that LCNEC's histologic subtype routing complexity, molecular profiling requirements, rapid progression surveillance, and clinical trial coordination demand. This guide explains why LCNEC tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the surgical, pathologic, molecular, oncologic, and clinical trial complexity of modern LCNEC management.
Why LCNEC Tech Platforms Require Specialized Monitoring Attention
LCNEC management is defined by the histologic subtype routing challenge (SCLC-like versus NSCLC-like LCNEC determines the chemotherapy backbone), the molecular profiling complexity that identifies actionable alterations in a small but therapeutically critical subset, the aggressive progression kinetics with rapid CT doubling times requiring frequent surveillance imaging, the rarity of LCNEC that makes clinical trial enrollment the preferred treatment pathway at specialized centers, and the diagnostic pitfall of distinguishing LCNEC from SCLC, atypical carcinoid, and NSCLC with neuroendocrine features — where platform failures in any domain create disruptions that directly affect chemotherapy backbone selection, actionable mutation detection, progression surveillance timing, and trial enrollment eligibility determination.
Histologic subtype routing platforms have critical treatment-selection impact. LCNEC subtype classification — where synaptophysin and chromogranin A expression confirms neuroendocrine differentiation, where RB1 immunohistochemistry (loss of nuclear staining) serves as a surrogate for RB1 mutation and identifies the SCLC-like molecular subtype best suited to platinum-etoposide, where STK11 mutation (by NGS) identifies the NSCLC-like subtype potentially better suited to platinum-pemetrexed, and where SCLC exclusion (by Ki-67 proliferation index, nuclear morphology, and cell size) prevents misclassification — requires platforms managing complex IHC panel results, molecular subtype routing logic, and multidisciplinary tumor board documentation that integrates pathology and molecular data to select the chemotherapy regimen. Monitor pathology and subtype routing platforms at 1-minute intervals during business hours.
Molecular profiling platforms must identify actionable alterations in a rare tumor. Comprehensive NGS panels detecting EGFR mutations, ALK fusions (relevant for alectinib in LCNEC with ALK rearrangement), ROS1 fusions, MET exon 14 skipping, BRAF V600E, RET fusions, and NTRK fusions — where the expected hit rate of ~5–10% for actionable alterations means that platforms failing to route molecular results to oncology teams before treatment initiation could delay the detection of a targetable alteration that changes treatment from chemotherapy to targeted therapy — require continuous platform availability for molecular result delivery with treatment routing. Monitor molecular profiling platforms at 1-minute intervals during business hours.
Rapid progression surveillance platforms must match LCNEC's aggressive kinetics. LCNEC doubling times on CT are among the fastest of any pulmonary neuroendocrine tumor — surveillance CT imaging scheduled at 6–8 week intervals during active treatment (more frequent than the 12-week standard for most NSCLC) — where platform failures delaying CT scheduling or result integration could allow undetected progression to accumulate for multiple doubling times before the next clinical visit. Monitor surveillance imaging platforms at 1-minute intervals during business hours.
Clinical trial enrollment dashboards support the preferred treatment pathway for rare LCNEC. LCNEC's rarity (3% of lung cancers) means that no randomized phase III trial has been completed defining standard-of-care; clinical trial enrollment is the preferred treatment at centers with available trials — where platforms managing LCNEC trial eligibility assessment (molecular eligibility criteria: RB1 status, STK11 status, PD-L1 expression; clinical eligibility: performance status, organ function, prior treatment), trial matching, informed consent documentation, and trial protocol compliance monitoring must be reliably available during the narrow enrollment window before first-line chemotherapy is initiated. Monitor clinical trial enrollment platforms at 1-minute intervals during business hours.
Brain surveillance platforms must address the high rate of CNS metastasis. LCNEC demonstrates a high rate of brain metastasis (20–40% during disease course), requiring MRI brain monitoring — where platforms scheduling and integrating serial brain MRI results, documenting stereotactic radiosurgery planning for oligometastatic brain disease, and managing prophylactic cranial irradiation records for SCLC-like LCNEC patients achieving complete response must be reliably available. Monitor brain surveillance platforms during business hours.
What to Monitor on an LCNEC Tech Platform
Histologic Subtype Routing and Pathology
Monitor neuroendocrine differentiation IHC records (synaptophysin, chromogranin A, CD56/NCAM, NSE), RB1 immunohistochemistry (surrogate for RB1 mutation; loss = SCLC-like subtype), Ki-67 proliferation index documentation (typically >50% in LCNEC, distinguishing from atypical carcinoid), mitotic count records (≥11 per 2 mm² required by WHO classification), necrosis documentation, SCLC exclusion records (cell size, nuclear morphology, CD44 expression, TTF-1 expression), combined SCLC-LCNEC composite tumor documentation, and multidisciplinary tumor board subtype routing records (SCLC-like → platinum-etoposide; NSCLC-like → platinum-pemetrexed) at 1-minute intervals during business hours. Alert immediately — subtype routing platform failures delay the IHC and molecular data integration that determines whether a newly diagnosed LCNEC patient receives platinum-etoposide or platinum-pemetrexed as the chemotherapy backbone.
Molecular Profiling and Actionable Alteration Detection
Monitor comprehensive NGS panel records (EGFR exon 19/21, KRAS G12C, STK11, KEAP1, KRAS, TP53, RB1, ALK fusion, ROS1 fusion, MET exon 14, BRAF V600E, RET fusion, NTRK1/2/3 fusion; minimum 500-gene panel recommended for LCNEC given therapeutic breadth), ALK FISH and IHC documentation, PD-L1 expression by IHC (22C3 pharmDx, SP263, 28-8 clone documentation), tumor mutation burden (TMB-H ≥10 mut/Mb for pembrolizumab eligibility), RET fusion FISH or RNA-seq records, NTRK fusion documentation (larotrectinib/entrectinib eligibility), and tissue adequacy assessment for NGS (cellularity percentage, DNA/RNA yield) at 1-minute intervals during business hours. Alert immediately — actionable alteration detection failures delay identification of EGFR mutations, ALK/ROS1/RET/NTRK fusions, or MET exon 14 skipping in LCNEC patients who would receive targeted therapy rather than chemotherapy — directly changing first-line treatment selection.
Platinum-Based Chemotherapy Administration
Monitor platinum-etoposide chemotherapy records (cisplatin 80 mg/m² or carboplatin AUC 5–6 day 1; etoposide 100–120 mg/m² days 1–3; cycle documentation, dose modification for hematologic toxicity, nephrotoxicity, and peripheral neuropathy; G-CSF prophylaxis records for febrile neutropenia risk), platinum-pemetrexed records (pemetrexed 500 mg/m² with vitamin B12 and folate supplementation; dose modification for renal impairment), carboplatin selection rationale records (when cisplatin contraindicated for renal impairment, hearing loss, or neuropathy), response assessment CT documentation at 2-cycle intervals, and dose-delay and dose-modification records at 1-minute intervals during chemotherapy sessions. Alert immediately — chemotherapy platform failures during active platinum infusion disrupt pharmacy verification, nursing administration records, and toxicity monitoring for agents with significant nephrotoxicity (cisplatin), myelosuppression (etoposide), and pulmonary toxicity (pemetrexed) profiles.
Surveillance CT and Rapid Progression Monitoring
Monitor CT chest/abdomen/pelvis scheduling at 6–8 week intervals during active treatment (accelerated versus standard 12-week NSCLC surveillance to match LCNEC's rapid kinetics), CT chest scheduling at 3-month intervals post-treatment completion, response assessment documentation (RECIST 1.1 criteria, target lesion measurement comparison), interval change documentation for rapid progression assessment, and CT brain scheduling for neurologic symptom evaluation at 1-minute intervals during business hours. Alert immediately — surveillance CT scheduling failures allow LCNEC progression to accumulate across multiple doubling-time intervals before detection, particularly critical for a tumor with median OS of 8–12 months in advanced disease where treatment-switch opportunities are narrow.
Brain Surveillance and CNS Metastasis Management
Monitor MRI brain scheduling for baseline staging and surveillance (every 3 months during active treatment for SCLC-like LCNEC given high CNS metastasis rate), stereotactic radiosurgery (SRS) planning documentation for oligometastatic brain disease, whole-brain radiation therapy (WBRT) documentation for bulky or multiple brain metastases, prophylactic cranial irradiation (PCI) documentation for SCLC-like LCNEC patients achieving complete or near-complete response (PCI 25 Gy in 10 fractions per SCLC analogy), and neuropsychological monitoring records for PCI-related cognitive effects at 1-minute intervals during business hours. Alert immediately — brain surveillance platform failures delay MRI scheduling in a population with 20–40% cumulative brain metastasis risk where early SRS intervention preserves neurocognitive function and OS versus delayed detection of bulky, symptomatic CNS disease.
Clinical Trial Enrollment and Eligibility Assessment
Monitor LCNEC-specific trial eligibility screening records (molecular eligibility: RB1 status, STK11 status, PD-L1 TPS, TMB; clinical eligibility: ECOG performance status 0–2, organ function criteria, prior therapy restrictions), trial matching documentation (LNET/LCNEC-specific trials; neuroendocrine tumor basket trials; immunotherapy combinations), informed consent documentation, protocol compliance monitoring records, correlative biomarker sample collection records (tumor tissue, ctDNA, peripheral blood for translational endpoints), and enrollment pipeline tracking (screen failure documentation, enrollment rate monitoring) at 1-minute intervals during business hours. Alert immediately — clinical trial enrollment platform failures during the pre-treatment eligibility assessment window may delay or preclude enrollment in LCNEC trials where the enrollment window closes once first-line treatment begins.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. LCNEC programs coordinate across thoracic surgery, molecular pathology, pulmonology, radiation oncology, medical oncology, neuroradiology, neurosurgery, and clinical trial operations — authentication failures simultaneously block every member of the multidisciplinary team managing a tumor where histologic subtype routing, molecular profiling, rapid surveillance imaging, and trial enrollment must all be coordinated within a narrow therapeutic window.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, molecular pathology reporting systems, chemotherapy administration platforms, surveillance imaging scheduling portals, brain MRI platforms, and clinical trial management systems. Certificate errors disrupt the subtype routing, molecular profiling, surveillance imaging, and trial coordination workflows that LCNEC's rare, aggressive, and molecularly heterogeneous presentation demands.
HIPAA and Oncology Data Privacy Considerations
LCNEC technology platforms handle sensitive PHI including RB1 loss documentation with implications for SCLC-like subtype classification and chemotherapy routing, STK11 and KEAP1 mutation records, comprehensive NGS panel results identifying actionable alterations for targeted therapy eligibility, PD-L1 expression and TMB documentation for immunotherapy eligibility, rapid surveillance CT records reflecting aggressive disease progression monitoring, brain MRI records for CNS metastasis documentation, prophylactic cranial irradiation records, platinum-etoposide and platinum-pemetrexed chemotherapy administration records, and clinical trial enrollment and correlative biomarker sample collection records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components.
For platforms managing clinical trial enrollment records — where correlative biomarker sample collection, randomization records, and protocol deviation documentation reflect both PHI and proprietary clinical trial data subject to FDA 21 CFR Part 11 electronic records requirements — platform availability and audit trail integrity standards must satisfy both HIPAA and clinical trial regulatory requirements. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance and clinical trial data integrity obligations for LCNEC programs managing this dual regulatory obligation.
Alerting Strategy for LCNEC Tech Platforms
Immediate alerting during chemotherapy administration: Platforms managing platinum-etoposide and platinum-pemetrexed prescribing, pharmacy verification, nursing administration, toxicity monitoring, and G-CSF prophylaxis during active infusion sessions. These cannot fail during chemotherapy administration.
Immediate alerting during radiation treatment sessions: Platforms managing thoracic IMRT, SRS planning for brain metastases, WBRT delivery, and PCI administration records during active radiation delivery.
Immediate business-hours alert: Histologic subtype routing platforms, molecular profiling and actionable alteration delivery, rapid surveillance CT scheduling, brain MRI scheduling, and clinical trial enrollment eligibility assessment. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Surveillance imaging result integration, clinical trial protocol compliance monitoring, correlative biomarker sample tracking, and LCNEC tumor registry platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms LCNEC platform availability from the geographies where high-volume thoracic oncology programs with molecular pathology subtype routing expertise, clinical trial access, and neuroendocrine tumor multidisciplinary teams concentrate — important for a rare tumor where institutional volume directly affects subtype routing accuracy and trial enrollment opportunities.
Status Page for LCNEC Care Team Communication
A real-time status page gives thoracic surgeons planning lobectomy for resectable LCNEC, molecular pathologists issuing RB1 IHC and NGS subtype reports, thoracic medical oncologists selecting platinum-etoposide versus platinum-pemetrexed based on molecular subtype, radiation oncologists managing thoracic IMRT and PCI, neuroradiologists interpreting brain MRI for CNS metastases, neurosurgeons planning SRS for oligometastatic brain disease, and clinical trial coordinators managing LCNEC trial enrollment immediate platform visibility without requiring inbound IT support contact. During a molecular subtype routing platform outage at the time of a multidisciplinary tumor board for a newly diagnosed LCNEC patient — where the thoracic oncologist requires RB1 IHC and STK11 NGS results to route the patient to platinum-etoposide or platinum-pemetrexed before the first chemotherapy cycle — a status page enables immediate contingency protocol activation ensuring that alternative molecular result access pathways and manual subtype classification documentation can be coordinated without platform-dependent delay.
Include the status page URL in molecular subtype routing downtime procedures, chemotherapy administration emergency workflows, brain surveillance scheduling fallback protocols, and clinical trial enrollment alternative access procedures.
Vigilmon Setup for LCNEC Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Histologic subtype routing / RB1 IHC / synaptophysin/chromogranin | 1 min | Slack + PagerDuty (business hours) | | Comprehensive NGS panel / actionable alteration routing | 1 min | Slack + PagerDuty (business hours) | | PD-L1 expression / TMB documentation | 1 min | Slack + PagerDuty (business hours) | | Platinum-etoposide / platinum-pemetrexed administration | 1 min | Slack + PagerDuty (infusion hours) | | Rapid surveillance CT (6–8 week intervals) | 1 min | Slack + PagerDuty (business hours) | | Brain MRI / CNS metastasis monitoring | 1 min | Slack + PagerDuty (business hours) | | SRS / WBRT / PCI delivery platforms | 1 min | Slack + PagerDuty (treatment hours) | | Clinical trial enrollment eligibility / protocol compliance | 1 min | Slack + PagerDuty (business hours) | | Surveillance imaging result integration | 2 min | Slack (business hours) | | Correlative biomarker sample tracking | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure histologic subtype routing (synaptophysin, chromogranin A, CD56, RB1 IHC) platforms with immediate business-hours alerting
- Add comprehensive NGS panel and actionable alteration routing platforms with immediate business-hours alerting
- Configure PD-L1 expression and TMB documentation platforms with immediate business-hours alerting
- Add platinum-etoposide and platinum-pemetrexed administration platforms with immediate infusion-hours alerting
- Configure rapid surveillance CT scheduling (6–8 week intervals) with immediate business-hours alerting
- Add brain MRI and CNS metastasis monitoring platforms with immediate business-hours alerting
- Configure SRS, WBRT, and PCI treatment delivery platforms with immediate treatment-hours alerting
- Add clinical trial enrollment eligibility assessment and protocol compliance monitoring with immediate business-hours alerting
- Configure surveillance imaging result integration and correlative biomarker sample tracking with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, molecular pathology, oncology, radiology, and trial management domains
- Add the status page URL to molecular subtype routing downtime procedures, chemotherapy administration emergency workflows, and trial enrollment alternative access procedures
Conclusion
LCNEC technology platforms are embedded in clinical decisions where histologic subtype routing platform availability at the time of a multidisciplinary tumor board for a 61-year-old patient with newly diagnosed stage IIIB LCNEC — where the thoracic pathologist's RB1 immunohistochemistry showing loss of nuclear staining in tumor cells alongside synaptophysin and chromogranin A positivity and Ki-67 of 75% identifies the SCLC-like molecular subtype that warrants platinum-etoposide chemotherapy rather than platinum-pemetrexed, where the comprehensive NGS panel result simultaneously identifies whether an actionable alteration (ALK fusion, EGFR mutation, MET exon 14) is present that would redirect treatment from cytotoxic chemotherapy to targeted therapy entirely, where PD-L1 TPS of 60% and TMB of 8 mut/Mb from the NGS panel determine immunotherapy eligibility in combination or sequencing with chemotherapy, and where the clinical trial coordinator requires eligibility screening results including RB1 status, STK11 mutation, and performance status to determine enrollment eligibility in the single available LCNEC-specific trial before first-line treatment is initiated — cannot be disrupted by platform outage at the precise tumor board session where histologic classification, molecular subtype routing, actionable alteration detection, immunotherapy eligibility, and trial enrollment determination must all be available simultaneously to a multidisciplinary team making the first-line treatment decision for a rare tumor where second-line options are limited and the therapeutic window is measured in months; where rapid surveillance CT platform availability during active platinum-etoposide chemotherapy — where the thoracic oncologist must schedule CT chest at 6-week intervals rather than the standard 12-week NSCLC interval given LCNEC's rapid doubling times, where the CT report documenting stable disease at week 6 confirms the patient should receive cycles 3–4 before reassessment rather than switching to second-line therapy prematurely, and where any new pulmonary nodule, mediastinal lymph node, or hepatic lesion at week 6 must be compared against baseline and identified with sufficient lead time to schedule restaging MRI brain and bone scan before the patient's clinical deterioration precludes further systemic therapy — cannot be delayed by scheduling platform unavailability when LCNEC's aggressive kinetics compress the therapeutic decision cycle to 6-week intervals; and where brain surveillance platform availability during routine clinical follow-up for a patient with SCLC-like LCNEC who achieved a complete response to 4 cycles of platinum-etoposide — where MRI brain documenting absence of CNS metastases at 3 months post-treatment supports prophylactic cranial irradiation consideration per SCLC analogy, and where PCI planning documents the dose, fractionation, and neuropsychological baseline assessment before 10-fraction WBRT — cannot be disrupted by platform unavailability at the narrow post-treatment assessment window where PCI eligibility determination requires simultaneous access to response records, performance status, and brain imaging results. A histologic subtype routing platform that fails when the pathologist is issuing the RB1 IHC result that determines platinum-etoposide versus platinum-pemetrexed for a LCNEC patient whose first-line regimen must be selected before tumor doubling allows symptomatic deterioration, an NGS platform inaccessible when the molecular oncologist must confirm ALK fusion status before initiating chemotherapy in an LCNEC patient who might have a targetable rearrangement redirecting treatment to alectinib, a rapid surveillance CT scheduling platform unavailable when the 6-week restaging scan must be booked at the precise interval that matches LCNEC's doubling-time kinetics — these are not IT incidents. They are clinical disruptions in the management of a rare, aggressive pulmonary neuroendocrine carcinoma whose histologic-molecular routing complexity, actionable mutation detection requirements, rapid progression surveillance obligations, and clinical trial enrollment dependency demand that subtype routing, molecular profiling, chemotherapy administration, and surveillance platforms are reliably available at every critical decision point.
Uptime monitoring gives LCNEC tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to thoracic oncology programs, molecular pathology laboratories, radiation oncology departments, and compliance auditors that platform operational reliability matches the histologic routing complexity, molecular profiling demands, aggressive surveillance obligations, and trial coordination requirements of modern LCNEC care.
Start monitoring your LCNEC care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #LCNEC #largecellneuroendocrine #lungcancer #neuroendocrine #RB1 #STK11 #synaptophysin #chromogranin #platinumetoposide #molecularprofiling #ALKfusion #EGFRmutation #clinicaltrial #neuroendocrinecarcinoma #thoraciconcology #cancertech #healthtech #digitalhealth #uptime #sre #HIPAA